Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

-

ABSTRACT

This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine. Detailed Description ABT-888 (Veliparib) or Poly(ADP-ribose)-polymerase (PARP) is a nuclear enzyme that recognizes deoxyribonucleic acid (DNA) damage and facilitates DNA repair. Inactive PARPs 1 and 2 bind to damaged DNA, which leads to their auto-activation. The resulting activated PARP then poly(ADP-ribosyl)ates many nuclear target proteins, including those that facilitate DNA repair of both single-stranded or double-stranded DNA breaks. Thus, PARP inhibition will result in less efficient DNA repair following a DNA damage insult. Since cancer cells are genetically unstable, often exhibiting complex karyotypes that include large deletions, insertions, and unbalanced translocations of chromosomal fragment, these cells are more susceptible than normal tissues to cytotoxicity induced by DNA-damaging agents.Of these, deficiencies in mismatch repair and homologous recombination are associated with the largest number of malignancies, including many sporadic TNBCs. These deficiencies render cells more dependent on PARP for DNA repair and, hence, are more prone to cytotoxicity induced by PARP inhibition. In particular, tumor cells with BRCA1 or BRCA2 deficiencies are exquisitely sensitive to PARP inhibition, even in the absence of any other insults. Identification of sporadic TNBC with defects in homologous recombination and mismatch repair independent of germline mutation of BRCA 1 and 2 is an active area of research interest. PARP-enabled DNA repair may also compensate for the loss of other repair pathways. Higher expression of PARP in cancer cells compared to normal cells has been linked to drug resistance and the overall ability of cancer cells to sustain genotoxic stress. The combination of platinum based chemotherapy and PARP inhibition may be most effective in TNBC, and particularly in subsets of TNBC. This combination may also be active in tumors with a germline BRCA1-deficiency and/or basal phenotype, since a defect in the DNA double-strand break repair pathway should increase sensitivity to these agents. The addition of a PARP inhibitor to platinum based chemotherapy may induce a "double hit" to tumor cells lacking homologous recombination without causing excess toxicity to normal cells. ABT-888 may be used in combination with the DNA damaging agent, cisplatin, to potentiate its cytotoxic effect and with vinorelbine to enhance tumor response rate. Safety and preliminary efficacy of veliparib in combination with cisplatin and vinorelbine in patients with advanced triple negative and BRCA-associated breast cancer has been reported. More... »

URL

https://clinicaltrials.gov/show/NCT02985658

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2581", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine.\n\nDetailed Description\nABT-888 (Veliparib) or Poly(ADP-ribose)-polymerase (PARP) is a nuclear enzyme that recognizes deoxyribonucleic acid (DNA) damage and facilitates DNA repair. Inactive PARPs 1 and 2 bind to damaged DNA, which leads to their auto-activation. The resulting activated PARP then poly(ADP-ribosyl)ates many nuclear target proteins, including those that facilitate DNA repair of both single-stranded or double-stranded DNA breaks. Thus, PARP inhibition will result in less efficient DNA repair following a DNA damage insult. Since cancer cells are genetically unstable, often exhibiting complex karyotypes that include large deletions, insertions, and unbalanced translocations of chromosomal fragment, these cells are more susceptible than normal tissues to cytotoxicity induced by DNA-damaging agents.Of these, deficiencies in mismatch repair and homologous recombination are associated with the largest number of malignancies, including many sporadic TNBCs. These deficiencies render cells more dependent on PARP for DNA repair and, hence, are more prone to cytotoxicity induced by PARP inhibition. In particular, tumor cells with BRCA1 or BRCA2 deficiencies are exquisitely sensitive to PARP inhibition, even in the absence of any other insults. Identification of sporadic TNBC with defects in homologous recombination and mismatch repair independent of germline mutation of BRCA 1 and 2 is an active area of research interest. PARP-enabled DNA repair may also compensate for the loss of other repair pathways. Higher expression of PARP in cancer cells compared to normal cells has been linked to drug resistance and the overall ability of cancer cells to sustain genotoxic stress. The combination of platinum based chemotherapy and PARP inhibition may be most effective in TNBC, and particularly in subsets of TNBC. This combination may also be active in tumors with a germline BRCA1-deficiency and/or basal phenotype, since a defect in the DNA double-strand break repair pathway should increase sensitivity to these agents. The addition of a PARP inhibitor to platinum based chemotherapy may induce a \"double hit\" to tumor cells lacking homologous recombination without causing excess toxicity to normal cells. ABT-888 may be used in combination with the DNA damaging agent, cisplatin, to potentiate its cytotoxic effect and with vinorelbine to enhance tumor response rate. Safety and preliminary efficacy of veliparib in combination with cisplatin and vinorelbine in patients with advanced triple negative and BRCA-associated breast cancer has been reported.", 
    "id": "sg:clinicaltrial.NCT02985658", 
    "keywords": [
      "protocol", 
      "patient", 
      "BRCA mutation", 
      "Triple", 
      "negative breast cancer", 
      "expanded access", 
      "continued maintenance", 
      "product", 
      "association", 
      "clinical trial participation", 
      "BRCA", 
      "access", 
      "monotherapy", 
      "discretion", 
      "cisplatin", 
      "vinorelbine", 
      "polymerase", 
      "poly ( ADP-ribose ) polymerase", 
      "nuclear enzyme", 
      "DNA", 
      "damage", 
      "repair", 
      "acid", 
      "poly", 
      "ADP-ribosyl", 
      "ATE", 
      "nuclear target", 
      "break", 
      "cancer cell", 
      "karyotype", 
      "large deletion", 
      "insertion", 
      "translocation", 
      "fragment", 
      "cell", 
      "normal tissue", 
      "cytotoxicity", 
      "damaging agent", 
      "deficiency", 
      "DNA Mismatch Repair", 
      "homologous recombination", 
      "large number", 
      "malignancy", 
      "TNBC", 
      "tumor cell", 
      "BRCA1 or BRCA2", 
      "absence", 
      "insult", 
      "defect", 
      "Germ-Line Mutation", 
      "BRCA-1", 
      "active area", 
      "research interest", 
      "repair pathway", 
      "expression", 
      "normal cell", 
      "drug resistance", 
      "overall ability", 
      "DNA damage", 
      "platinum-based chemotherapy", 
      "subset", 
      "Neoplasm", 
      "BRCA1 deficiency", 
      "phenotype", 
      "double-strand", 
      "increase sensitivity", 
      "agent", 
      "poly ( ADP-ribose ) polymerase inhibitor", 
      "toxicity", 
      "cytotoxic effect", 
      "tumor response", 
      "safety", 
      "preliminary efficacy", 
      "breast"
    ], 
    "name": "Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02985658"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00023.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.431072.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.34477.33", 
        "type": "Organization"
      }
    ], 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1111/j.1432-1033.1980.tb04426.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002677445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-1144-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014176542"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0165-6147(00)01902-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027600994"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci20761", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035267327"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036499081", 
          "https://doi.org/10.1038/nature03443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature03445", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039649759", 
          "https://doi.org/10.1038/nature03445"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/pr.54.3.375", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062438745"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081727449", 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02985658"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02985658'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02985658'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02985658'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02985658'


 

This table displays all metadata directly associated to this object as RDF triples.

121 TRIPLES      14 PREDICATES      97 URIs      81 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02985658 schema:about anzsrc-for:2581
2 anzsrc-for:3142
3 schema:description This is an expanded access protocol to allow continued maintenance therapy with ABT-888 (veliparib) for three patients with metastatic triple negative breast cancer who are currently receiving the investigational product in association with clinical trial participation. Additionally, the protocol will enroll up to 7 new patients with metastatic BRCA associated or triple negative breast cancer to allow for additional access to veliparib monotherapy, or at the investigator's discretion, veliparib in combination with cisplatin and/or vinorelbine. Detailed Description ABT-888 (Veliparib) or Poly(ADP-ribose)-polymerase (PARP) is a nuclear enzyme that recognizes deoxyribonucleic acid (DNA) damage and facilitates DNA repair. Inactive PARPs 1 and 2 bind to damaged DNA, which leads to their auto-activation. The resulting activated PARP then poly(ADP-ribosyl)ates many nuclear target proteins, including those that facilitate DNA repair of both single-stranded or double-stranded DNA breaks. Thus, PARP inhibition will result in less efficient DNA repair following a DNA damage insult. Since cancer cells are genetically unstable, often exhibiting complex karyotypes that include large deletions, insertions, and unbalanced translocations of chromosomal fragment, these cells are more susceptible than normal tissues to cytotoxicity induced by DNA-damaging agents.Of these, deficiencies in mismatch repair and homologous recombination are associated with the largest number of malignancies, including many sporadic TNBCs. These deficiencies render cells more dependent on PARP for DNA repair and, hence, are more prone to cytotoxicity induced by PARP inhibition. In particular, tumor cells with BRCA1 or BRCA2 deficiencies are exquisitely sensitive to PARP inhibition, even in the absence of any other insults. Identification of sporadic TNBC with defects in homologous recombination and mismatch repair independent of germline mutation of BRCA 1 and 2 is an active area of research interest. PARP-enabled DNA repair may also compensate for the loss of other repair pathways. Higher expression of PARP in cancer cells compared to normal cells has been linked to drug resistance and the overall ability of cancer cells to sustain genotoxic stress. The combination of platinum based chemotherapy and PARP inhibition may be most effective in TNBC, and particularly in subsets of TNBC. This combination may also be active in tumors with a germline BRCA1-deficiency and/or basal phenotype, since a defect in the DNA double-strand break repair pathway should increase sensitivity to these agents. The addition of a PARP inhibitor to platinum based chemotherapy may induce a "double hit" to tumor cells lacking homologous recombination without causing excess toxicity to normal cells. ABT-888 may be used in combination with the DNA damaging agent, cisplatin, to potentiate its cytotoxic effect and with vinorelbine to enhance tumor response rate. Safety and preliminary efficacy of veliparib in combination with cisplatin and vinorelbine in patients with advanced triple negative and BRCA-associated breast cancer has been reported.
4 schema:keywords ADP-ribosyl
5 ATE
6 BRCA
7 BRCA mutation
8 BRCA-1
9 BRCA1 deficiency
10 BRCA1 or BRCA2
11 DNA
12 DNA Mismatch Repair
13 DNA damage
14 Germ-Line Mutation
15 Neoplasm
16 TNBC
17 Triple
18 absence
19 access
20 acid
21 active area
22 agent
23 association
24 break
25 breast
26 cancer cell
27 cell
28 cisplatin
29 clinical trial participation
30 continued maintenance
31 cytotoxic effect
32 cytotoxicity
33 damage
34 damaging agent
35 defect
36 deficiency
37 discretion
38 double-strand
39 drug resistance
40 expanded access
41 expression
42 fragment
43 homologous recombination
44 increase sensitivity
45 insertion
46 insult
47 karyotype
48 large deletion
49 large number
50 malignancy
51 monotherapy
52 negative breast cancer
53 normal cell
54 normal tissue
55 nuclear enzyme
56 nuclear target
57 overall ability
58 patient
59 phenotype
60 platinum-based chemotherapy
61 poly
62 poly ( ADP-ribose ) polymerase
63 poly ( ADP-ribose ) polymerase inhibitor
64 polymerase
65 preliminary efficacy
66 product
67 protocol
68 repair
69 repair pathway
70 research interest
71 safety
72 subset
73 toxicity
74 translocation
75 tumor cell
76 tumor response
77 vinorelbine
78 schema:name Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer
79 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02985658
80 schema:sdDatePublished 2019-03-07T15:27
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher Nf5eda4122b8e41ae9aa57a99ea4bd804
83 schema:sponsor https://www.grid.ac/institutes/grid.34477.33
84 https://www.grid.ac/institutes/grid.431072.3
85 schema:subjectOf sg:pub.10.1038/nature03443
86 sg:pub.10.1038/nature03445
87 https://app.dimensions.ai/details/publication/pub.1081727449
88 https://doi.org/10.1016/s0165-6147(00)01902-7
89 https://doi.org/10.1111/j.1432-1033.1980.tb04426.x
90 https://doi.org/10.1124/pr.54.3.375
91 https://doi.org/10.1158/1078-0432.ccr-1144-3
92 https://doi.org/10.1172/jci20761
93 schema:url https://clinicaltrials.gov/show/NCT02985658
94 sgo:license sg:explorer/license/
95 sgo:sdDataset clinical_trials
96 rdf:type schema:MedicalStudy
97 Nf5eda4122b8e41ae9aa57a99ea4bd804 schema:name Springer Nature - SN SciGraph project
98 rdf:type schema:Organization
99 anzsrc-for:2581 schema:inDefinedTermSet anzsrc-for:
100 rdf:type schema:DefinedTerm
101 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
102 rdf:type schema:DefinedTerm
103 sg:pub.10.1038/nature03443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036499081
104 https://doi.org/10.1038/nature03443
105 rdf:type schema:CreativeWork
106 sg:pub.10.1038/nature03445 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039649759
107 https://doi.org/10.1038/nature03445
108 rdf:type schema:CreativeWork
109 https://app.dimensions.ai/details/publication/pub.1081727449 schema:CreativeWork
110 https://doi.org/10.1016/s0165-6147(00)01902-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027600994
111 rdf:type schema:CreativeWork
112 https://doi.org/10.1111/j.1432-1033.1980.tb04426.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002677445
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1124/pr.54.3.375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062438745
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1158/1078-0432.ccr-1144-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014176542
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1172/jci20761 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035267327
119 rdf:type schema:CreativeWork
120 https://www.grid.ac/institutes/grid.34477.33 schema:Organization
121 https://www.grid.ac/institutes/grid.431072.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...